FDA Proposes Study to Improve DTC Print Ad Disclosures

June 16, 2017
Drugs Regulatory Affairs
The FDA is proposing an experimental study to examine the effects of risk disclosures and fine print in direct-to-consumer drug advertising.

To View This Article:

Login

Subscribe To FDAnews

Upcoming Events

Featured Products

Featured Stories

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More